C34 J44
Conditions
Interventions
Group 1: As a part of this study, 98 ml blood will be drawn from each patient who will be enrolled. They will be also asked to fill out a short questionnaire regarding their lifestyle.
Sponsors
Hummingbird Diagnostics GmbH
Eligibility
Sex/Gender
All
Age
55 Years to 80 Years
Inclusion criteria
Inclusion criteria: The following patients are included: Group 1) Patients with suspected early stage lung cancer (stage I / II); and Group 2) patients with benign lung diseases (e.g. COPD or benign mass in the lungs); between the ages of 55 and 80 years (male or female). Further inclusion criteria are a current or ex-smoker status with = 30 pack years and with nicotine abstinence <15 years (if ex-smoker).
Exclusion criteria
Exclusion criteria: Exclusion criteria are: • known chronic, infectious diseases (HIV, HCV, HBV) • an advanced cancer treated curatively in the past 5 years • immunomodulatory or neoadjuvant therapy that has already started • invasive diagnostics before inclusion in the study • anemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establishment of an expression catalog (base matrix) of the short-chain and long-chain RNAs of the cells of the peripheral blood. | — |
Secondary
| Measure | Time frame |
|---|---|
| The aim is also to evaluate how exactly different commercially available blood collection systems (PAXgene, Tempus, Norgen cfRNA, Mitra unit) map the physiological miRNA profiles of the blood. | — |
Countries
Germany
Contacts
Public ContactKaja Tikk
Hummingbird Diagnostics GmbH
Outcome results
None listed